Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of "Buy" by Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been given a consensus recommendation of "Buy" by the eight research firms that are currently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $71.40.

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a report on Monday, September 9th. HC Wainwright restated a "buy" rating and set a $63.00 price target on shares of Arcturus Therapeutics in a report on Tuesday, October 1st. Leerink Partnrs raised Arcturus Therapeutics to a "strong-buy" rating in a research report on Monday, August 12th. Finally, Leerink Partners assumed coverage on shares of Arcturus Therapeutics in a research report on Monday, August 12th. They set an "outperform" rating and a $70.00 price objective on the stock.

Arcturus Therapeutics Trading Up 3.0 %

Arcturus Therapeutics stock traded up $0.53 during trading hours on Tuesday, hitting $18.35. 329,643 shares of the stock traded hands, compared to its average volume of 465,710. Arcturus Therapeutics has a one year low of $17.26 and a one year high of $45.00. The company has a market cap of $494.17 million, a PE ratio of -6.77 and a beta of 2.64. The firm's 50-day moving average price is $20.78 and its two-hundred day moving average price is $24.44.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($1.85) by $1.21. The business had revenue of $49.86 million during the quarter, compared to analyst estimates of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same quarter last year, the firm posted ($1.98) earnings per share. On average, sell-side analysts expect that Arcturus Therapeutics will post -2.6 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Pad Chivukula sold 12,000 shares of the business's stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total transaction of $249,120.00. Following the completion of the transaction, the chief operating officer now directly owns 435,334 shares of the company's stock, valued at $9,037,533.84. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 15.30% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Arcturus Therapeutics by 45.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company's stock worth $52,819,000 after purchasing an additional 712,650 shares during the period. ARK Investment Management LLC grew its holdings in Arcturus Therapeutics by 6.9% during the third quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company's stock valued at $48,765,000 after purchasing an additional 136,074 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its stake in Arcturus Therapeutics by 22.4% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company's stock worth $38,061,000 after acquiring an additional 286,546 shares during the period. Millennium Management LLC grew its position in shares of Arcturus Therapeutics by 250.1% during the second quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company's stock worth $13,515,000 after purchasing an additional 396,505 shares in the last quarter. Finally, Empire Life Investments Inc. purchased a new stake in Arcturus Therapeutics during the 3rd quarter valued at approximately $3,498,000. 94.54% of the stock is owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.